Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1984 Dec;83(4):951–958. doi: 10.1111/j.1476-5381.1984.tb16536.x

Acute and chronic effects of the benzodiazepine receptor ligand FG 7142: proconvulsant properties and kindling.

H J Little, D J Nutt, S C Taylor
PMCID: PMC1986992  PMID: 6097329

Abstract

The effects of the acute and chronic administration of the beta-carboline benzodiazepine receptor ligand, FG 7142 were studied in mice. On acute administration FG 7142 (at doses between 10 and 40 mg kg-1) lowered seizure thresholds to infused pentylenetetrazol (PTZ) but showed an unusual dose-response curve in that higher doses had less effect. The duration of action was considerably longer than that of other beta-carbolines, such as ethyl-beta-carboline-3-carboxylate (beta CCE). During repeated administration, doses of FG 7142 which were initially proconvulsant subsequently produced generalized seizures on average in 60% of animals after 12 once daily treatments. This seemed to be a form of chemical kindling. The effects of different drug administration regimes were studied. Once daily dosage was shown to be the optimum for kindling production, and was therefore used for subsequent experiments. Kindling lasted for at least one month after 12 single once daily doses of 40 mg kg-1 (FG 7142). The administration of the benzodiazepine antagonist Ro 15-1788 concurrent with FG 7142 prevented kindling. When Ro 15-1788 was given to kindled animals along with a challenge dose of FG 7142, it prevented the expression of kindled seizures. These data show that kindling is mediated via the benzodiazepine receptor.

Full text

PDF
951

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aranko K., Mattila M. J., Seppälä T. Development of tolerance and cross-tolerance to the psychomotor actions of lorazepam and diazepam in man. Br J Clin Pharmacol. 1983 May;15(5):545–552. doi: 10.1111/j.1365-2125.1983.tb02088.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Braestrup C., Nielsen M. GABA reduces binding of 3H-methyl beta-carboline-3-carboxylate to brain benzodiazepine receptors. Nature. 1981 Dec 3;294(5840):472–474. doi: 10.1038/294472a0. [DOI] [PubMed] [Google Scholar]
  3. Braestrup C., Nielsen M., Olsen C. E. Urinary and brain beta-carboline-3-carboxylates as potent inhibitors of brain benzodiazepine receptors. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2288–2292. doi: 10.1073/pnas.77.4.2288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Braestrup C., Schmiechen R., Neef G., Nielsen M., Petersen E. N. Interaction of convulsive ligands with benzodiazepine receptors. Science. 1982 Jun 11;216(4551):1241–1243. doi: 10.1126/science.6281892. [DOI] [PubMed] [Google Scholar]
  5. Church M. W., Johnson L. C. Mood and performance of poor sleepers during repeated use of flurazepam. Psychopharmacology (Berl) 1979 Mar 28;61(3):309–316. doi: 10.1007/BF00432277. [DOI] [PubMed] [Google Scholar]
  6. Cowen P. J., Green A. R., Nutt D. J. Ethyl beta-carboline carboxylate lowers seizure threshold and antagonizes flurazepam-induced sedation in rats. Nature. 1981 Mar 5;290(5801):54–55. doi: 10.1038/290054a0. [DOI] [PubMed] [Google Scholar]
  7. Dorow R., Horowski R., Paschelke G., Amin M. Severe anxiety induced by FG 7142, a beta-carboline ligand for benzodiazepine receptors. Lancet. 1983 Jul 9;2(8341):98–99. doi: 10.1016/s0140-6736(83)90076-4. [DOI] [PubMed] [Google Scholar]
  8. File S. E., Lister R. G., Nutt D. J. The anxiogenic action of benzodiazepine antagonists. Neuropharmacology. 1982 Oct;21(10):1033–1037. doi: 10.1016/0028-3908(82)90118-6. [DOI] [PubMed] [Google Scholar]
  9. File S. E. Recovery from lorazepam tolerance and the effects of a benzodiazepine antagonist (RO 15-1788) on the development of tolerance. Psychopharmacology (Berl) 1982;77(3):284–288. doi: 10.1007/BF00464581. [DOI] [PubMed] [Google Scholar]
  10. File S. E. Tolerance to the anti-pentylenetetrazole effects of diazepam in the mouse. Psychopharmacology (Berl) 1983;79(2-3):284–286. doi: 10.1007/BF00427828. [DOI] [PubMed] [Google Scholar]
  11. Hunkeler W., Möhler H., Pieri L., Polc P., Bonetti E. P., Cumin R., Schaffner R., Haefely W. Selective antagonists of benzodiazepines. Nature. 1981 Apr 9;290(5806):514–516. doi: 10.1038/290514a0. [DOI] [PubMed] [Google Scholar]
  12. Lister R. G., Greenblatt D. J., Abernethy D. R., File S. E. Pharmacokinetic studies on Ro 15-1788, a benzodiazepine receptor ligand, in the brain of the rat. Brain Res. 1984 Jan 2;290(1):183–186. doi: 10.1016/0006-8993(84)90752-2. [DOI] [PubMed] [Google Scholar]
  13. Little H. J. The effects of benzodiazepine agonists, inverse agonists and Ro 15-1788 on the responses of the superior cervical ganglion to GABA in vitro. Br J Pharmacol. 1984 Sep;83(1):57–68. doi: 10.1111/j.1476-5381.1984.tb10119.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Möhler H. Benzodiazepine receptors: differential interaction of benzodiazepine agonists and antagonists after photoaffinity labeling with flunitrazepam. Eur J Pharmacol. 1982 Jun 4;80(4):435–436. doi: 10.1016/0014-2999(82)90092-9. [DOI] [PubMed] [Google Scholar]
  15. Nutt D. J., Cowen P. J., Batts C. C., Grahame-Smith D. G., Green A. R. Repeated administration of subconvulsant doses of GABA antagonist drugs. I. Effect on seizure threshold (kindling). Psychopharmacology (Berl) 1982;76(1):84–87. doi: 10.1007/BF00430762. [DOI] [PubMed] [Google Scholar]
  16. Nutt D. J., Cowen P. J., Green A. R. On the measurement in rats of the convulsant effect of drugs and the changes which follow electroconvulsive shock. Neuropharmacology. 1980 Oct;19(10):1017–1023. doi: 10.1016/0028-3908(80)90014-3. [DOI] [PubMed] [Google Scholar]
  17. Nutt D. J., Cowen P. J., Little H. J. Unusual interactions of benzodiazepine receptor antagonists. Nature. 1982 Feb 4;295(5848):436–438. doi: 10.1038/295436a0. [DOI] [PubMed] [Google Scholar]
  18. Petersen E. N., Jensen L. H., Honoré T., Braestrup C. Differential pharmacological effects of benzodiazepine receptor inverse agonists. Adv Biochem Psychopharmacol. 1983;38:57–64. [PubMed] [Google Scholar]
  19. Petersen E. N., Paschelke G., Kehr W., Nielsen M., Braestrup C. Does the reversal of the anticonflict effect of phenobarbital by beta-CCE and FG 7142 indicate benzodiazepine receptor-mediated anxiogenic properties? Eur J Pharmacol. 1982 Aug 27;82(3-4):217–221. doi: 10.1016/0014-2999(82)90517-9. [DOI] [PubMed] [Google Scholar]
  20. Polc P., Bonetti E. P., Schaffner R., Haefely W. A three-state model of the benzodiazepine receptor explains the interactions between the benzodiazepine antagonist Ro 15-1788, benzodiazepine tranquilizers, beta-carbolines, and phenobarbitone. Naunyn Schmiedebergs Arch Pharmacol. 1982 Dec;321(4):260–264. doi: 10.1007/BF00498510. [DOI] [PubMed] [Google Scholar]
  21. Post R. M., Rose H. Increasing effects of repetitive cocaine administration in the rat. Nature. 1976 Apr 22;260(5553):731–732. doi: 10.1038/260731a0. [DOI] [PubMed] [Google Scholar]
  22. Robertson H. A., Riives M. L. A benzodiazepine antagonist is an anticonvulsant in an animal model for limbic epilepsy. Brain Res. 1983 Jul 4;270(2):380–382. doi: 10.1016/0006-8993(83)90619-4. [DOI] [PubMed] [Google Scholar]
  23. Rosenberg H. C., Chiu T. H. Regional specificity of benzodiazepine receptor down-regulation during chronic treatment of rats with flurazepam. Neurosci Lett. 1981 Jun 12;24(1):49–52. doi: 10.1016/0304-3940(81)90357-8. [DOI] [PubMed] [Google Scholar]
  24. Segal D. S., Mandell A. J. Long-term administration of d-amphetamine: progressive augmentation of motor activity and stereotypy. Pharmacol Biochem Behav. 1974 Mar-Apr;2(2):249–255. doi: 10.1016/0091-3057(74)90060-4. [DOI] [PubMed] [Google Scholar]
  25. Stein L., Berger B. D. Psychopharmacology of 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one (lorazepam) in squirrel monkey and rat. Arzneimittelforschung. 1971 Jul;21(7):1073–1078. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES